July 2025 in “Journal of Investigative Dermatology” Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
May 2025 in “Acta Dermato Venereologica” Alopecia areata patients have higher risks of infections, lymphoma, heart issues, and death.
April 2025 in “Journal of Cosmetic Dermatology” Azathioprine is a safe and effective long-term treatment for severe alopecia areata, significantly improving hair regrowth.
April 2025 in “Acta Dermato Venereologica” Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
February 2025 in “Diagnostics” Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.
January 2025 in “Journal of Plastic Reconstructive & Aesthetic Surgery” Two L-PRP treatments improve hair density in mild to moderate alopecia.
January 2025 in “Dermatologic Therapy” Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
January 2025 in “Dermatologic Therapy” Minoxidil with betamethasone is the most effective for hair regrowth in alopecia areata.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
November 2024 in “International Journal of Dermatology” LC-OCT is a useful noninvasive tool for diagnosing and monitoring alopecia areata.
September 2024 in “Archives of Dermatological Research”
July 2024 in “Dermatology Practical & Conceptual” LC-OCT helps accurately diagnose different types of infant hair loss without invasive methods.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
June 2024 in “Current Developments in Nutrition” Omega-3 fatty acids may not help and could harm hair loss improvement in middle-aged or elderly men.
June 2024 in “Current Developments in Nutrition” Eating more fish may lower heart disease risk in women but not in men.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
April 2024 in “Journal of burn care & research” Neck burn scar contracture recurrence is more likely with larger neck defects, and closer follow-up can help detect it sooner.
March 2024 in “Clinical and Experimental Dermatology” Having an appendectomy may increase the risk of developing alopecia areata.
Many severe COVID-19 patients experienced temporary hair loss, but most regrew hair within six months.
February 2024 in “Skin research and technology” LC-OCT is a promising tool for diagnosing and monitoring Alopecia areata.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
February 2024 in “Scientific Reports” Topical minoxidil and dietary supplements improved hair regrowth in children with hair loss from chemotherapy.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
December 2023 in “Journal of Thoracic Disease” Increased EGFR gene variations may predict chemotherapy outcomes in small cell lung cancer patients.
October 2023 in “Cancers” Skin cancer in sun-exposed areas is more likely to come back.
Older men with late-onset lupus have a higher mortality rate than women.
May 2023 in “Acta Oncologica” 5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.
October 2021 in “Journal of Investigative Dermatology” COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.
March 2020 in “Research Square (Research Square)” Ankylosing spondylitis does not increase the risk of hair loss.